Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients

Trial Profile

Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Recombinant staphylokinase Supergene (Primary) ; Tenecteplase
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms FORMAT-1
  • Sponsors Supergene
  • Most Recent Events

    • 03 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top